Quipt Home Medical (QIPT – Research Report), the Healthcare company, was revisited by a Wall Street analyst today. Analyst Stefan Quenneville from Echelon Wealth Partners reiterated a Buy rating, with a C$11.75 price target.
Quenneville has an average return of 9.4% when recommending Quipt Home Medical.
According to TipRanks.com, Quenneville is ranked #7751 out of 8379 analysts.
Currently, the analyst consensus on Quipt Home Medical is a Moderate Buy with an average price target of C$12.25, implying a 39.0% upside from current levels. In a report released today, Stifel Nicolaus also maintained a Buy rating on the stock with a C$12.75 price target.
The company has a one-year high of C$9.75 and a one-year low of C$5.33. Currently, Quipt Home Medical has an average volume of 72.41K.
Protech Home Medical Corp provides in-home monitoring equipment, supplies and services to patients. The company’s services consist of Daily & Ambulatory Aides, Power Mobility, INR Self-Testing, Respiratory Equipment Rental, Home ventilation, Oxygen Therapy, and Sleep Apnea & PAP Treatment.
The company’s shares closed last Tuesday at C$8.18.
Read More on TSE:QIPT:
- Quipt Home Medical Reports Record Second Quarter Fiscal 2023 Financial Results Posting Revenue Growth of 73% and Adjusted EBITDA Growth of 86%
- Quipt Home Medical Corp (QIPT) Q2 Earnings Cheat Sheet
- Quipt Home Medical Announces Date and Time for Fiscal Q2 2023 Conference Call and Audio Webcast
- Quipt Home Medical receives conditional approval to graduate to TSX
- Quipt Home Medical Receives Conditional Approval to Graduate to the Toronto Stock Exchange
